Literature DB >> 4063711

The application of the linear-quadratic dose-effect equation to fractionated and protracted radiotherapy.

R G Dale.   

Abstract

The linear-quadratic (LQ) dose-effect formalism is currently providing new perspectives into the ways in which alterations in the dose per fraction in conventional radiotherapy may be used to bring about improved results with respect to early or late normal tissue reactions. In this paper, using a model initially developed by Roesch, the LQ equations are explored further in terms of dose-rate rather than dose. By the incorporation of one other parameter, mu, which relates to the rate of repair of sub-lethal radiation damage, a more general formalism is obtained. In particular, equations are derived which can be used to examine the relative effectiveness of different treatment regimes, including those involving decaying sources. Such equations are of wider applicability than other LQ derivations which relate only to dose-response relationships. The extended equations, which are fully consistent with the existing LQ method, are also shown to lead directly to other independently established, relationships for protracted irradiation. The nature of the link between high and low dose-rate treatments is discussed, and some worked examples provide indications of how the new equations may be used to assess further the potential clinical benefits of low dose-rate treatments and permanent implants.

Entities:  

Mesh:

Year:  1985        PMID: 4063711     DOI: 10.1259/0007-1285-58-690-515

Source DB:  PubMed          Journal:  Br J Radiol        ISSN: 0007-1285            Impact factor:   3.039


  143 in total

1.  Methodology to incorporate biologically effective dose and equivalent uniform dose in patient-specific 3-dimensional dosimetry for non-Hodgkin lymphoma patients targeted with 131I-tositumomab therapy.

Authors:  Hanan Amro; Scott J Wilderman; Yuni K Dewaraja; Peter L Roberson
Journal:  J Nucl Med       Date:  2010-03-17       Impact factor: 10.057

Review 2.  21 years of biologically effective dose.

Authors:  J F Fowler
Journal:  Br J Radiol       Date:  2010-07       Impact factor: 3.039

3.  Bio-effect model applied to 131I radioimmunotherapy of refractory non-Hodgkin's lymphoma.

Authors:  Peter L Roberson; Hanan Amro; Scott J Wilderman; Anca M Avram; Mark S Kaminski; Matthew J Schipper; Yuni K Dewaraja
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-12-21       Impact factor: 9.236

4.  International brachytherapy practice patterns: a survey of the Gynecologic Cancer Intergroup (GCIG).

Authors:  Akila N Viswanathan; Carien L Creutzberg; Peter Craighead; Mary McCormack; Takafumi Toita; Kailash Narayan; Nicholas Reed; Harry Long; Hak-Jae Kim; Christian Marth; Jacob C Lindegaard; Annmarie Cerrotta; William Small; Edward Trimble
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-12-22       Impact factor: 7.038

5.  Protracted ruthenium treatment of recurrent pterygium.

Authors:  Y Robert; L Pauli; P Gysin; B Gloor; P Hendrickson
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1992       Impact factor: 3.117

6.  [(111)In]DOTATOC as a dosimetric substitute for kidney dosimetry during [(90)Y]DOTATOC therapy: results and evaluation of a combined gamma camera/probe approach.

Authors:  Alexander Stahl; Sylvia Schachoff; Ambros Beer; Anna Winter; Hans Jürgen Wester; Klemens Scheidhauer; Markus Schwaiger; Ingo Wolf
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-04-28       Impact factor: 9.236

7.  Calculation of the biological effective dose for piecewise defined dose-rate fits.

Authors:  Robert F Hobbs; George Sgouros
Journal:  Med Phys       Date:  2009-03       Impact factor: 4.071

8.  Application of radiobiological dosimetry to radionuclide directed therapy.

Authors:  W T Millar
Journal:  Br J Cancer Suppl       Date:  1990-07

9.  Biologically effective dose and definitive radiation treatment for localized prostate cancer: treatment gaps do affect the risk of biochemical failure.

Authors:  P Sanpaolo; V Barbieri; D Genovesi
Journal:  Strahlenther Onkol       Date:  2014-03-04       Impact factor: 3.621

10.  On the need to compensate for edema-induced dose reductions in preplanned (131)Cs prostate brachytherapy.

Authors:  Z Jay Chen; Jun Deng; Kenneth Roberts; Ravinder Nath
Journal:  Int J Radiat Oncol Biol Phys       Date:  2007-11-05       Impact factor: 7.038

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.